Anti-Human VEGF (Bevacizumab) - Fc Reduced HRP Biosimilar (IVMB0504)
- SKU:
- IVMB0504
- Antibody Type:
- HRP Biosimilar
- Modifications:
- HRP-Conjugated
- Applications:
- IHC, FC, ELISA, Drug Development, Pharmacokinetics
Description
| Product Name: | Anti-Human VEGF (Bevacizumab) - Fc Reduced HRP Biosimilar |
| SKU: | IVMB0504 |
| Size: | 100 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | A4.6.1 |
| Target: | VEGF |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | ELISA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Muted |
| Synonyms: | Vascular Endothelial Growth Factor; VEGF-A; VEGFA; Vascular Permeability Factor; VPF |
| Product Concentration: | 0.5 mg/ml |
| Immunogen: | Recombinant human VEGF. |
| Applications and Recommended Usage: | FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA |
| Antigen Distribution: | VEGF is widely expressed in the thyroid, prostate, and various other tissues. |
| Formulation: | This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only. |
| Additional Reported Applications For Relevant Conjugates: | BNIPWB |
Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth. Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
Related Products
Anti-Human VEGF (Bevacizumab) - HRP Biosimilar (IVMB0502)
Anti-Human VEGF (Bevacizumab) - Fc Reduced Biotin Biosimilar (IVMB0503)
